Enovis Corp (ENOV) Stock Price & Analysis
Enovis Corp (ENOV) rose 1.18% to USD 23.96 as of June 10, 2026 at 03:48 UTC, according to Nexqual real-time market data.
ENOV last closed at USD 23.68; the session ranged USD 23.5–24.57 on volume of 813,908 shares. Market capitalization is $1.38B, with a 52-week range of USD 20.82–36.82 (NYQ). Source: Nexqual, June 10, 2026 at 03:48 UTC.
Key Statistics (as of June 10, 2026 at 03:48 UTC)
| Price | USD 23.96 |
|---|---|
| Change | ▲ 1.18% (up) |
| Previous Close | USD 23.68 |
| Open | USD 23.99 |
| Day Range | USD 23.5 – 24.57 |
| 52-Week Range | USD 20.82 – 36.82 |
| Volume | 813,908 shares |
| Market Cap | $1.38B |
| Exchange | NYQ |
Technical Analysis (ENOV)
Nexqual's technical model rates ENOV "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.56 (neutral) |
| vs SMA50 | Below (USD 24.09) |
| MACD | -0.37 (negative) |
Analyst Ratings (ENOV)
Wall Street analysts rate ENOV "None" based on 11 analysts, with a mean price target of USD 43 (range USD 33–55), per Nexqual as of June 10, 2026 at 03:48 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 43 |
| High Target | USD 55 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ENOV)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.85 |
| Revenue Estimate | $583.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.89 vs est 0.81 ▲ beat |
| 2025-12-31 | USD 0.95 vs est 0.84 ▲ beat |
| 2025-09-30 | USD 0.75 vs est 0.65 ▲ beat |
| 2025-06-30 | USD 0.79 vs est 0.72 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financials & Fundamentals (ENOV)
| Total Revenue | $2.28B |
|---|---|
| Revenue Growth (YoY) | +5.40% |
| Gross Margin | +61.00% |
| Operating Margin | +3.64% |
| Profit Margin | -49.91% |
| ROE | -55.35% |
| Debt / Equity | 95.34 |
| Current Ratio | 2.04 |
| Total Cash | $33.13M |
| Total Debt | $1.41B |
| Free Cash Flow | $206.90M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financial Health Score (ENOV)
Nexqual rates Enovis Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:48 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 61%, operating 4% |
| Balance Sheet | Mixed — $33M cash vs $1.41B debt |
| Cash Flow | Solid — FCF $207M, 9% margin |
| Efficiency | Critical — ROE -55%, ROA 1.1% |
Ownership (ENOV)
| Insider Ownership | +1.62% |
|---|---|
| Institutional Ownership | +119.66% |
| Shares Outstanding | 57.56M |
| Float | 56.59M |
| Short % of Float | +17.92% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Leadership (ENOV)
Enovis Corp is led by Damien McDonald (age 60), CEO & Director, per Nexqual as of June 10, 2026 at 03:48 UTC.
| CEO & Director | Damien McDonald (age 60) |
|---|---|
| Senior VP & CFO | Phillip Benjamin Berry (age 46) |
| Group President Prevention & Recovery | Terry D. Ross (age 55) |
| Group President of Reconstructive | Louie Vogt (age 44) |
| Vice President of Investor Relations | Kyle William Rose |
Major Backers & Investors (ENOV)
Notable institutional backers of Enovis Corp include American Century Companies Inc, Rubric Capital Management LP, Davenport & Co LLC, according to Nexqual as of June 10, 2026 at 03:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 12.93% |
| Rubric Capital Management LP | 4.26% |
| Davenport & Co LLC | 4.24% |
| Paradigm Capital Management | 3.09% |
| Hood River Capital Management LLC | 3.05% |
| Fidelity | 2.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 25.66% |
| Vanguard Group | 17.96% |
| Dimensional Fund Advisors | 4.42% |
| State Street | 4.17% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
From Enovis Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Class I includes devices with the lowest patient risk and are those for which safety and effectiveness can be assured by adherence to the FDA's general controls for medical devices, including compliance with applicable portions of the Quality System Regulation ("QSR") facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials.
- We serve orthopedic surgeons and healthcare systems worldwide with products for shoulder, hip, knee, and extremity reconstruction and fixation, including both primary and revision procedures. 4 Our offerings are supported by proprietary surgical techniques, surgeon education, and digital tools that enhance preoperative planning, intraoperative precision, and postoperative recovery.
- The comprehensive range of products we offer enables us to reach a diverse customer base through multiple distribution channels with numerous opportunities to increase our growth across our markets.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESAB | ESAB Corporation | USD 88.48 | ▲ 0.6% |
| AZTA | Azenta, Inc. | USD 22.72 | ▲ 0.13% |
| EPAC | Enerpac Tool Group Corp. | USD 35.04 | ▲ 4.75% |
| ZWS | Zurn Elkay Water Solutions Corp | USD 48.32 | ▲ 2.01% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:48 UTC. This page is informational and not investment advice.